The Global Burden of Alcohol-associated Cirrhosis and Cancer in Young and Middle-aged Adults
- PMID: 38428708
- PMCID: PMC11344661
- DOI: 10.1016/j.cgh.2024.02.011
The Global Burden of Alcohol-associated Cirrhosis and Cancer in Young and Middle-aged Adults
Abstract
Alcohol is a substance that impacts premature mortality and morbidity.1 The liver is invariably subjected to the impact of alcohol, which can result in cirrhosis and cancer. Alcohol also has detrimental effects that extend beyond the liver. While traditionally associated with advanced age, emerging data reported a rising burden of cancers and alcohol-associated liver disease in the young.1-3 Thus, the primary objective was to evaluate the trend of alcohol-associated cirrhosis and cancer in young and middle-aged adults (aged 15-49) utilizing the Global Burden of Disease Study (GBD) 2019.4 We chose the age group less than 50 years old based on the definition of early-onset cancer and the inherent selection of the age group in the GBD database.4-6 The detailed methods are provided in the Supplementary Appendix. Briefly, data were sourced from population-based cancer registries, vital registration systems, or verbal autopsy studies. Verbal autopsy is a well-established approach for monitoring health, providing valuable information on mortality patterns and the reasons behind deaths in areas lacking robust medical death certification processes. The researchers employed the Cause of Death Ensemble model to estimate the burden linked to cancer and cirrhosis associated with alcohol use.
Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest
These authors disclose the following: Cheng Han Ng has served as a consultant for Boxer Capital. Hirokazu Takahashi has received research grants from Astellas Pharma, AbbVie GK, and Sysmex. Daniel Q. Huang has served as an advisory board member for Eisai and receives funding support from the Singapore Ministry of Health’s National Medical Research Council under its NMRC Research Training Fellowship (MOH-000595–01). Mazen Noureddin has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Terns, Siemens, and Roche Diagnostic; has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking, and Zydus; and is a minor shareholder or has stocks in Anaetos, Rivus Pharma, and Viking. Vincent Chen’s institution has received research grants from KOWA and AstraZeneca. The remaining author discloses no conflicts.
Figures

References
-
- Danpanichkul P, et al. Am J Gastroenterol 2023.
-
- Danpanichkul P, et al. J Gastroenterol Hepatol 2023;38:2053–2060. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources